1. Pfizer ( PFE) sells pharmaceuticals including Dimetapp, Dristan and Halcion.

Quarter: Pfizer's third-quarter net income plummeted 70% to $866 million and earnings per share dropped 74% to 11 cents. Revenue advanced 39% to $16 billion. The gross margin declined from 88% to 87% and the operating margin fell from 38% to 31%. Pfizer has $22 billion of cash and $44 billion of debt, translating to a quick ratio of 1.6 and a debt-to-equity ratio of 0.5. Pfizer's 12-month sales have increased 46%, though net profit has fallen 25%.

Valuation: Pfizer's stock trades at a forward earnings multiple of 7.3, a book value multiple of 1.5 and a sales multiple of 2, 38%, 68% and 36% discounts to pharmaceuticals industry averages. But, its cash flow multiple of 13 represents a premium of 18%. A PEG ratio, calculated by dividing the P/E ratio by analysts' long-term growth forecast, of 0.3 demonstrates a 70% discount to estimated fair value. Pfizer is a consensus buy-side value pick, but has fallen 8.5% in 2010.

Dividend: Pfizer pays a quarterly dividend of 18 cents, translating to a one-year yield of 4.3% and an elevated payout ratio of 94%. Pfizer halved its dividend to 16 cents in 2009 amid recession, but has since lifted it.

-- Written by Jake Lynch in Boston.

To see these stocks in action, visit the 8 Cheapest Dow Dividend Stocks Portfolio on Stockpickr.


Become a fan of TheStreet on Facebook.

Disclosure: TheStreet's editorial policy prohibits staff editors, reporters and analysts from holding positions in any individual stocks.

If you liked this article you might like

Bank Stocks Move Higher Ahead of Federal Reserve Meeting

CEOs Focused on Tax Reform, Business Roundtable Survey Says

All Eyes on the Godfather of Central Banking as Fed Has Huge Meeting This Week

Chase Hires Amazon Customer-Service Exec as Digital's Rise Reshapes Branches

Here Are Monday's Hottest Stocks as the Dow Reaches New Records